EMERGENT-5: Cobenfy and Treatment Durability

In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist.
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.
• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 85
• Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?